It has been about a month since the last earnings report for GSK (GSK). Shares have lost about 2.1% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent ...
GlaxoSmithKline plans to close its vaccine plant in Dresden, destroying 641 jobs. The IGBCE union and works council are ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline today and set a price target of £20.00. Papadakis covers the Healthcare sector, focusing on stocks such as ...
GSK plc, aka GlaxoSmithKline, is rated a Buy at or below $45 due to relative undervaluation and a balanced, diversified portfolio. GSK's recent CEO transition and solid Q2 earnings have improved ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Berenberg Bank analyst Kerry Holford reiterated a Hold rating on GlaxoSmithKline today and set a price target of p2,200.00. According to TipRanks, Holford is a 4-star analyst with an average return of ...
GSK (GSK) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.09 per share a year ago. These figures are ...
GlaxoSmithKline (GSK) will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology, and inflammation (RI&I) as well as oncology, through a collaboration ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results